At the virtual PREDiCT: Imaging Modalities for Oncology Drug Development Summit we will reveal the strategy behind the multimodal applications to understand how this information can determine clinical candidate success.
Join us in Boston with 60+ experts alongside organisations such as National Institute of Health, Genentech, MD Anderson Cancer Institute, Bristol Myers Squibb and more and utilize industry insight behind the latest imaging modalities to monitor immune responses in a safe and non-invasive manner, enabling you to accelerate your oncology drug development with confidence.
Oncology drug developers face a challenge to quickly understand drug targeted response to deliver safe products to patients. Effectively incorporating imaging is instrumental to improve understanding of the complex interactions between tumor and the immune system, lowering downstream risk of candidate failure.
The PREDiCT: Imaging Modalities for Oncology Drug Development Summit, will be the pioneering platform across preclinical and clinical stages to guide your application of multimodal imaging to enhance therapeutic success. Bringing together imaging experts from drug developers and leading academics across 3 days we will provide you with leading strategic applications behind targeted drug response to fast-track your clinical oncology pipeline.